Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study

Author： Eser Daniela Schüle Cornelius Baghai Thomas Floesser Anette Krebs-Brown Axel Enunwa Michaela Motte Stephan Engel Rolf Kucher Klaus Rupprecht Rainer

Publisher： Springer Publishing Company

ISSN： 0033-3158

Source： Psychopharmacology, Vol.192, Iss.4, 2007-07, pp. : 479-487

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Evaluation of Early Efficacy Endpoints for Proof-of-Concept Trials

By Chen Cong

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 2, 2013-03 ,pp. : 413-424

Taylor & Francis Ltd

Access to resources Recommend Favorite

Safety and Proof-of-Concept Efficacy of Inhaled Drug Loaded Nano- and Immunonanoparticles in a c-Raf Transgenic Lung Cancer Model

Current Cancer Drug Targets, Vol. 13, Iss. 1, 2013-01 ,pp. : 11-29

Bentham Science Publishers

Access to resources Recommend Favorite

Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease

By Lockwood Peter Ewy Wayne Hermann David Holford Nick

Pharmaceutical Research, Vol. 23, Iss. 9, 2006-09 ,pp. : 2050-2059

Springer Publishing Company

Access to resources Recommend Favorite

When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy

Current Pharmaceutical Design, Vol. 21, Iss. 26, 2015-01 ,pp. : 3788-3796

Bentham Science Publishers

Access to resources Recommend Favorite

Population Pharmacokinetic Model Characterizing 24‐Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 8, 2015-08 ,pp. : 454-464

John Wiley & Sons Inc

Access to resources Recommend Favorite